Burgdorf – Ypsomed successfully implements turnaround strategy and signs three new Injection Systems contracts with GlaxoSmithKline (GSK), Palatin Technologies, Inc. and Pharmstandard.
The Ypsomed Group succeeded in successfully implementing the turnaround strategy in the 2013/14 financial year, posting a profit in all business sectors. Operating profit, at CHF 15.6 million, has more than tripled. One driver of this success was the insulin business centered around the mylife OmniPod patch pump, sales of which doubled once again during the year under review. The Burgdorf-based diabetes specialist is ideally positioned for the future, having signed contracts with no fewer than three companies for injection systems. Ypsomed is involved in projects and negotiations regarding injection systems with a large number of pharmaceutical and biotechnology companies.
